Thermo Fisher Scientific (TMO) has been the focus of various updates including Q4 earnings, future outlook, insider trading, staffing changes and strategic partnerships. In its Q4 2025 statement, the company exceeded expectations and saw revenue growth. Its future outlook for 2026, however, fell below estimates due to anticipated cuts in research funding. This triggered a decrease in its stock price. TMO's partnership with tech giant NVIDIA to integrate advanced artificial intelligence into lab workflows suggests the firm's commitment to staying at the forefront of technological innovation. Notable asset management companies have adjusted their holdings in TMO, indicating continued investor interest. It's worth highlighting TD Cowen's maintained buy rating and the raised price target by Citigroup. Despite a steady performance and a constructive long-term outlook, TMO has guided cautious profit expectations.
Thermo Fisher Scientific TMO News Analytics from Wed, 10 Sep 2025 07:00:00 GMT to Sat, 31 Jan 2026 21:22:47 GMT -
Rating 3
- Innovation 7
- Information 8
- Rumor 2
